Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2019.296 | A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer | Dr. LOONG Herbert Ho Fung |
| 2019.493 | A Phase 1 Study of BOS172738 in Patients with Advanced Solid Tumors with RET Gene Alterations including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC) | Dr. LOONG Herbert Ho Fung |
| 2019.554 | A Phase 1, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects of Chinese Descent With Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 105) |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2019.376 | A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study) |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2020.056 | LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2017.347 | A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2017.172 | DETECTION AND QUANTIFICATION OF T790M and C797S MUTATIONS VIA DIGITAL DROPLET POLYERMASE CHAIN REACTION (ddPCR) IN LUNG CANCER PATIENTS ON OSIMERTINIB TREATMENT |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2016.493 | An Open-Label, Multicenter, Phase 1 Study with Expansion Cohorts of Ramucirumab or Necitumumab in Combination with Osimertinib in Patients with Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer after Progression on First-Line EGFR TKI Therapy |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2016.104 | A retrospective review of Epidemiology, Treatment Patterns, Prognostic Factors and Survival Outcomes of Sarcoma patients in Hong Kong | Dr. LOONG Herbert Ho Fung |
| 2016.076 | An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2025.235 | A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR) | Dr. LOONG Herbert Ho Fung |
| 2024.441 | A Phase 2, Open-label Study Evaluating STRO-002, an Anti-folate Receptor Alpha (FOLR1) Antibody-Drug Conjugate, in Subjects with Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Expressing FOLR1 | Dr. LOONG Herbert Ho Fung |
| 2024.425 | An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients with Advanced Tumors | Dr. LOONG Herbert Ho Fung |
| 2024.397 | Beamion LUNG-2: A Phase III, open-label, randomized, active-controlled, multi-centre trial evaluating orally administered zongertinib (BI 1810631) compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | Dr. LOONG Herbert Ho Fung |
| 2024.347 | Cross-cultural adaptation and validation of the Oxford dyspnoea word cue set for stimulation of emotional processing in lung cancer patients | Dr. LOONG Herbert Ho Fung |
| 2024.248 | A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) | Dr. LOONG Herbert Ho Fung |
| 2024.319 | An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | Dr. LOONG Herbert Ho Fung |
| 2025.359 | A two-part phase 1 open-label safety and pharmacokinetic study of intravenous RC220 in combination with doxorubicin in adult patients with solid tumours | Dr. LOONG Herbert Ho Fung |
| 2024.269 | A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations. | Dr. LOONG Herbert Ho Fung |
| 2025.182 | Effectiveness of Instant Messages-delivered Physical Activity e-Coaching and Training (IMPACT) Intervention on Cancer-Related Cognitive Impairment in Lung Cancer Survivors: A Randomized Controlled Trial | Dr. LOONG Herbert Ho Fung |
| 2024.592 | A Phase 2 Study Evaluating the Efficacy, Safety,Tolerability, and Pharmacokinetics of AMG 193 in Subjects with Methylthioadenosine Phosphorylase (MTAP)-deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) | Dr. LOONG Herbert Ho Fung |
| 2024.576 | A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) | Dr. LOONG Herbert Ho Fung |
| 2025.365 | A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Platinum-based Chemotherapy in Combination with Pembrolizumab, as First-line Therapy in Participants with Locally Advanced Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06) | Dr. LOONG Herbert Ho Fung |
| 2025.317 | Effectiveness of a Mindfulness-Oriented Respiratory Distress Symptom Intervention for Patients with Lung Cancer and Its Association with Brain Activity Changes | Dr. LOONG Herbert Ho Fung |
| 2025.096 | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer | Dr. LOONG Herbert Ho Fung |
| 2025.308 | A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312) | Dr. LOONG Herbert Ho Fung |
| 2018.422 | A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies |
Dr. LOONG Herbert H.F. 龍浩鋒 |
| 2019.518 | A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors |
Dr. LOONG Herbert H.F. 龍浩鋒 |
| 2019.609 | A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF OZURIFTAMAB VEDOTIN (BA3021) ALONE AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | Dr. LOONG Herbert H.F. |
| 2019.585 | A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab as Consolidation Therapy in Patients with Locally Advanced, Unresectable, Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed following Definitive, Platinum-Based, Chemoradiation Therapy (PACIFIC 5) |
Dr. LOONG Herbert H.F. 龍浩鋒醫生 |
| 2020.515 | Determining Engrailed-2 (EN2) Concentration in Urine Samples for Clinical Development of a Urine Lateral Flow Assay for Screening Urinary Tract Cancers |
Dr. LOONG Herbert H.F. 龍浩鋒醫生 |
| 2015.632 | A Randomized, Placebo Controlled Phase 3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1) |
Dr. LOONG Herbert H.F. 龍浩鋒 |
| 2015.155 | A multicenter randomized, open-label, phase II/III study, to compare the efficacy of NBTXR3, implanted as intratumor injection and activated by radiotherapy, versus radiotherapy alone in patients with locally advanced soft tissue sarcoma of the extremity and trunk wall. |
Dr. LOONG Herbert H.F. 龍浩鋒 |
| 2016.625 | A Phase I/IIa Study of BMS 986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects with Select Advanced Solid Tumors |
Dr. LOONG Herbert 龍浩鋒 |
| 2015.257 | A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine |
Dr. LOONG Herbert 龍浩鋒 |
| 2016.164 | A PILOT RANDOMIZED OPEN-LABELED STUDY COMPARING A STRUCTURED TITRATION METHOD OF IMMEDIATE- AND SUSTAINED-RELEASE OXYCODONE VERSUS OPIOIDS TITRATION OF INVESTIGATORS’ CHOICE IN ADVANCED CANCER PATIENTS IN HONG KONG | Dr. LOONG Herbert |
| 2014.457 | A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients with metastatic colorectal cancer | Prof. LOONG Herbert |
| 2016.162 | A Feasibility Study Investigating the Presence of Intra- and Inter-tumoural Heterogeneity in Gastrointestinal Stromal Tumours and Its Potential Impact on Treatment Response, Monitoring and Patients’ Survival | Dr. LOONG Herbert |
| 2016.165 | An open-label phase II study of pembrolizumab in East Asian patients with advanced/metastatic acral lentiginous melanoma |
Dr. LOONG Herbert 龍浩鋒 |
| 2020.197 | Blood-based Technology for the Detection of Epidermal Growth Factor Receptor Exon 20 Insertion in Patients with Advanced Stage Lung Cancer | Dr. LOONG Herbert |
| 2021.495 | Reduction of Polypharmacy in Frail Elderly Patients in Hong Kong Using STOPPFrail Criteria |
Dr LOO Chi Wah 盧志華 |
| 2024.038 | Deciphering the role of macrophage metabolic reprogramming in immunotherapy resistance of non-alcoholic steatohepatitis-hepatocellular carcinoma | Dr. LONG Xiaohang |
| 2025.014 | Deciphering the regulation and function of lipid-associated macrophages in immunotherapy resistance of hepatocellular carcinoma |
Prof. LONG Xiaohang Xiaohang LONG |
| 2025.341 | Establishment of a Novel Non-Invasive Biomarker Panel in Peripheral Blood Mononuclear Cells for Predicting Immunotherapy Response in Hepatocellular Carcinoma | Prof. LONG Xiaohang |
| 2019.468 | The prevalence of chromosomal abnormalities in fetuses with different degree of cerebral ventriculomegaly and the association of neurodevelopmental outcome after birth | Dr. LOK Wing Yi |
| 2017.654 | Deep learning algorithm for the detection of of diabetic retinopathy and/or age-related macular degeneration in a Chinese population |
Dr. LOK Ka Hing 駱家慶 |
| 2015.167 | Evaluating effect of strabismus surgery on reading-related skills in Chinese school-aged children with intermittent exotropia and constant exotropia |
Dr. LOK Julie Ying Ching 駱映晴 |
| 2016.417 | Visual outcome and refractive status in first 3 years of age in laser-treated high risk pre-threshold Type 1 retinopathy of prematurity (ROP): A 6 year retrospective review in Hong Kong population a tertiary centre in Hong Kong |
Dr. LOK Julie Ying Ching 駱映晴 |
| 2009.176 | A randomized study of prolonged pretreatment with gonadotrophin releasing hormone agonist (GnRHa) prior to frozen-thawed embryo transfer (FET) cycles in patients with endometriosis | Dr. Lok Ingrid Hung |
| 2012.077 | An Investigation into the Biology of Circulating Nucleic in Patients with Systemic Lupus Erythematosus by Next-Generation Sequencing | Prof Lo Yuk Ming Dennis |
Page 108 of 269.